Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study

Luca Cantarini, Rosaria Talarico, Elena Generali, Giacomo Emmi, Giuseppe Lopalco, Luisa Costa, Elena Silvestri, Francesco Caso, Rossella Franceschini, Rolando Cimaz, Florenzo Iannone, Mauro Galeazzi, Carlo Selmi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Aim: The primary aim of this study was to explore the safety profile of biologic treatments in Behçet's disease (BD), based on their mechanism of action; the secondary aim was to study any potential variation in terms of retention rate according to each single drug. Method: We studied a total of 85 treatment regimens with biologic agents from 64 patients. The total follow-up was calculated as 8640 patient-years (anti-tumor necrosis factor [TNF]-alpha 7.020, anti-interleukin [IL]-beta 1.368). Cumulative rates of drug retention were studied using the Kaplan-Meier plot and covariates in the regression model included the mechanism of action of the biologic agent, other concomitant therapies, disease duration, sex, age at start of drug therapy; for each confounding factor hazard ratios (HR) were calculated. Results: The most frequently prescribed biologic treatments were anti-TNF-alpha agents (79%), while anti-IL1-beta was used in the remaining regimens. Concomitant disease-modifying antirheumatic drugs were prescribed in 36% of patients, mainly cyclosporine and methotrexate, while in 35/85 regimens low-dose glucocorticoids were associated. During the follow-up, in all but one regimen the safety profile was free of any adverse events or serious adverse events; we observed only one case of endocarditis, reported during the 10th month of etanercept. Conclusion: Data from a large multicenter cohort suggest that anti-TNF-alpha and anti-IL1-beta agents are characterized by an excellent safety profile in BD.

Original languageEnglish
JournalInternational Journal of Rheumatic Diseases
DOIs
Publication statusAccepted/In press - 2015

Fingerprint

Biological Factors
Observational Studies
Cohort Studies
Safety
Tumor Necrosis Factor-alpha
Antirheumatic Agents
Interleukins
Therapeutics
Endocarditis
Methotrexate
Pharmaceutical Preparations
Cyclosporine
Glucocorticoids
Drug Therapy

Keywords

  • Anakinra
  • Biotherapies
  • Canakinumab
  • Interleukin-1 (IL-1)
  • Tumor necrosis factor (TNF)-alpha

ASJC Scopus subject areas

  • Rheumatology

Cite this

Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. / Cantarini, Luca; Talarico, Rosaria; Generali, Elena; Emmi, Giacomo; Lopalco, Giuseppe; Costa, Luisa; Silvestri, Elena; Caso, Francesco; Franceschini, Rossella; Cimaz, Rolando; Iannone, Florenzo; Galeazzi, Mauro; Selmi, Carlo.

In: International Journal of Rheumatic Diseases, 2015.

Research output: Contribution to journalArticle

Cantarini, L, Talarico, R, Generali, E, Emmi, G, Lopalco, G, Costa, L, Silvestri, E, Caso, F, Franceschini, R, Cimaz, R, Iannone, F, Galeazzi, M & Selmi, C 2015, 'Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study', International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185X.12732
Cantarini, Luca ; Talarico, Rosaria ; Generali, Elena ; Emmi, Giacomo ; Lopalco, Giuseppe ; Costa, Luisa ; Silvestri, Elena ; Caso, Francesco ; Franceschini, Rossella ; Cimaz, Rolando ; Iannone, Florenzo ; Galeazzi, Mauro ; Selmi, Carlo. / Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. In: International Journal of Rheumatic Diseases. 2015.
@article{b2b1e1d50b5f47cf87ccc7a72dbcb096,
title = "Safety profile of biologic agents for Beh{\cc}et's disease in a multicenter observational cohort study",
abstract = "Aim: The primary aim of this study was to explore the safety profile of biologic treatments in Beh{\cc}et's disease (BD), based on their mechanism of action; the secondary aim was to study any potential variation in terms of retention rate according to each single drug. Method: We studied a total of 85 treatment regimens with biologic agents from 64 patients. The total follow-up was calculated as 8640 patient-years (anti-tumor necrosis factor [TNF]-alpha 7.020, anti-interleukin [IL]-beta 1.368). Cumulative rates of drug retention were studied using the Kaplan-Meier plot and covariates in the regression model included the mechanism of action of the biologic agent, other concomitant therapies, disease duration, sex, age at start of drug therapy; for each confounding factor hazard ratios (HR) were calculated. Results: The most frequently prescribed biologic treatments were anti-TNF-alpha agents (79{\%}), while anti-IL1-beta was used in the remaining regimens. Concomitant disease-modifying antirheumatic drugs were prescribed in 36{\%} of patients, mainly cyclosporine and methotrexate, while in 35/85 regimens low-dose glucocorticoids were associated. During the follow-up, in all but one regimen the safety profile was free of any adverse events or serious adverse events; we observed only one case of endocarditis, reported during the 10th month of etanercept. Conclusion: Data from a large multicenter cohort suggest that anti-TNF-alpha and anti-IL1-beta agents are characterized by an excellent safety profile in BD.",
keywords = "Anakinra, Biotherapies, Canakinumab, Interleukin-1 (IL-1), Tumor necrosis factor (TNF)-alpha",
author = "Luca Cantarini and Rosaria Talarico and Elena Generali and Giacomo Emmi and Giuseppe Lopalco and Luisa Costa and Elena Silvestri and Francesco Caso and Rossella Franceschini and Rolando Cimaz and Florenzo Iannone and Mauro Galeazzi and Carlo Selmi",
year = "2015",
doi = "10.1111/1756-185X.12732",
language = "English",
journal = "International Journal of Rheumatic Diseases",
issn = "1756-1841",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study

AU - Cantarini, Luca

AU - Talarico, Rosaria

AU - Generali, Elena

AU - Emmi, Giacomo

AU - Lopalco, Giuseppe

AU - Costa, Luisa

AU - Silvestri, Elena

AU - Caso, Francesco

AU - Franceschini, Rossella

AU - Cimaz, Rolando

AU - Iannone, Florenzo

AU - Galeazzi, Mauro

AU - Selmi, Carlo

PY - 2015

Y1 - 2015

N2 - Aim: The primary aim of this study was to explore the safety profile of biologic treatments in Behçet's disease (BD), based on their mechanism of action; the secondary aim was to study any potential variation in terms of retention rate according to each single drug. Method: We studied a total of 85 treatment regimens with biologic agents from 64 patients. The total follow-up was calculated as 8640 patient-years (anti-tumor necrosis factor [TNF]-alpha 7.020, anti-interleukin [IL]-beta 1.368). Cumulative rates of drug retention were studied using the Kaplan-Meier plot and covariates in the regression model included the mechanism of action of the biologic agent, other concomitant therapies, disease duration, sex, age at start of drug therapy; for each confounding factor hazard ratios (HR) were calculated. Results: The most frequently prescribed biologic treatments were anti-TNF-alpha agents (79%), while anti-IL1-beta was used in the remaining regimens. Concomitant disease-modifying antirheumatic drugs were prescribed in 36% of patients, mainly cyclosporine and methotrexate, while in 35/85 regimens low-dose glucocorticoids were associated. During the follow-up, in all but one regimen the safety profile was free of any adverse events or serious adverse events; we observed only one case of endocarditis, reported during the 10th month of etanercept. Conclusion: Data from a large multicenter cohort suggest that anti-TNF-alpha and anti-IL1-beta agents are characterized by an excellent safety profile in BD.

AB - Aim: The primary aim of this study was to explore the safety profile of biologic treatments in Behçet's disease (BD), based on their mechanism of action; the secondary aim was to study any potential variation in terms of retention rate according to each single drug. Method: We studied a total of 85 treatment regimens with biologic agents from 64 patients. The total follow-up was calculated as 8640 patient-years (anti-tumor necrosis factor [TNF]-alpha 7.020, anti-interleukin [IL]-beta 1.368). Cumulative rates of drug retention were studied using the Kaplan-Meier plot and covariates in the regression model included the mechanism of action of the biologic agent, other concomitant therapies, disease duration, sex, age at start of drug therapy; for each confounding factor hazard ratios (HR) were calculated. Results: The most frequently prescribed biologic treatments were anti-TNF-alpha agents (79%), while anti-IL1-beta was used in the remaining regimens. Concomitant disease-modifying antirheumatic drugs were prescribed in 36% of patients, mainly cyclosporine and methotrexate, while in 35/85 regimens low-dose glucocorticoids were associated. During the follow-up, in all but one regimen the safety profile was free of any adverse events or serious adverse events; we observed only one case of endocarditis, reported during the 10th month of etanercept. Conclusion: Data from a large multicenter cohort suggest that anti-TNF-alpha and anti-IL1-beta agents are characterized by an excellent safety profile in BD.

KW - Anakinra

KW - Biotherapies

KW - Canakinumab

KW - Interleukin-1 (IL-1)

KW - Tumor necrosis factor (TNF)-alpha

UR - http://www.scopus.com/inward/record.url?scp=84940055654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940055654&partnerID=8YFLogxK

U2 - 10.1111/1756-185X.12732

DO - 10.1111/1756-185X.12732

M3 - Article

AN - SCOPUS:84940055654

JO - International Journal of Rheumatic Diseases

JF - International Journal of Rheumatic Diseases

SN - 1756-1841

ER -